CEO Who Led for 12 Years Steps Down Ahead of $18 Billion Buyout Completion

Hologic, Inc. (NASDAQ: HOLX), a women’s healthcare diagnostics company, announced that Chairman, President and CEO Steve MacMillan will retire upon the closing of its take-private transaction with Blackstone and TPG. The company has secured all required regulatory approvals, and the deal is expected to close around April 7. A successor CEO will be named at closing.

On April 7, the roughly $18.3 billion transaction (approximately ₩24 trillion) closed, Hologic delisted from Nasdaq, and became a privately held company under an investment vehicle led by Blackstone and TPG. MacMillan stepped down after more than 12 years as CEO, and Joe Almeida, former head of Baxter International, was appointed the new chief executive.

Headquartered in Massachusetts, Hologic is a medical technology firm specializing in women’s health. Its core products include diagnostic imaging systems for breast and cervical cancer, molecular diagnostic platforms, and surgical devices. Women’s healthcare and diagnostic equipment are viewed as global medtech segments with strong long-term growth potential amid aging populations and a growing emphasis on preventive care.